Division of the major birch pollen allergen, bet v 1, into two non-anaphylactic fragments

Susanne Vrtala, Kora Hirtenlehner, Luca Vangelista, Annalisa Pastore, Hans Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Rudolf Valenta

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


We have expressed in Escherichia coli two halves of the major birch pollen allergen, Bet v 1. Both fragments representing the complete 17-kD allergen were purified to homogeneity. In contrast to the complete recombinant, Bet v 1, the fragments had almost completely lost their IgE-binding capacity and exhibited a random coil structure as analyzed by circular dichroism. The ability of the recombinant fragments to trigger histamine release from allergic patients’ basophils as well as their capacity to elicit skin reactions were also largely abolished. Both non-anaphylactic Bet v 1 fragments carried the majority of T cell epitopes and may therefore be considered as safe tools for immunotherapy of tree pollen and associated food allergy.

Original languageEnglish
Pages (from-to)246-248
Number of pages3
JournalInternational Archives of Allergy and Immunology
Issue number1-3
Publication statusPublished - Jan 1 1997


  • IgE
  • Immunotherapy
  • Recombinant birch pollen allergen (Bet v 1)
  • Skin testing
  • T cell vaccine
  • Type I allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Division of the major birch pollen allergen, bet v 1, into two non-anaphylactic fragments'. Together they form a unique fingerprint.

Cite this